First day of trading in Arcede Pharma
Today is the first day of trading in Arcede Pharma. The company's main focus is on developing a new type of inhaled treatment for chronic obstructive pulmonary disease (COPD) and severe asthma.Arcede develops candidates for effective new drugs for chronic obstructive pulmonary disease (COPD) and severe asthma. The company's business concept is to develop drug candidates based on patent-pending compounds that have shown favorable results in preclinical studies compared to what is currently considered standard treatment. Arcede's lead candidate is designated RCD405, which is currently in